ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta.
FA
402 PT
1.376 PT
5.700 PT CHADS FAPx 1,8 FAPn 2
627 PT
End pointPlacebo (%/y)Dronedarone (%/y) HR (95% CI)p Stroke ( ) Stroke or TIA ( ) Fatal stroke ( ) Stroke, ACS, or CV death ( ) <0.001 Stroke, ACS, or all-cause death ( ) PT
Purpose The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation. ArmsAssigned Interventions 1: ExperimentalDrug: dronedarone (SR33589) 400mg bid 2: Active ComparatorDrug: amiodarone 600mg daily for 28 days, then 200mg daily Ages Eligible for Study: 21 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No 504 PT
112 PT
SINCOPE
Estratificación de riesgo
504 PT
Incidencia de Muerte súbita Myerburg RJ. Circulation.1998;97: GROUP >2 factores de riesgo Pacientes con enfermedad coronaria Pacientes con FE <35%, e ICC Pacientes con PCR previa Pacientes con IAM FE deprimida y TV Población global 300,000200,000100,0000 Nº. De MS anual Incidencia de MS (% grupo)
High energy implant rates pmp Source: Eucomed
490 PT
651 PT
206 PT
45 PT
7.001 PT